ESPE Abstracts (2015) 84 P-2-411

ESPE2015 Poster Category 2 GH & IGF (40 abstracts)

Estimation of Adipsin, Omentin and Vaspin Concentration in Prepubertal Children with GH Deficiency before and after 6 Months of GH Treatment

Agnieszka Rudzka-Kocjan a & Mieczyslaw Szalecki a,


aChildren’s Memorial Health Institute, Warsaw, Poland; bUniversity of Jan Kochanowski, Kielce, Poland


Background: GH deficiency (GHD) is usually associated with excess of abdominal fat tissue and increased risk of developing cardiovascular diseases. Adipose tissue produces different adipocytokines that could explain the relationship between excess of fat tissue and increased metabolic risk. Adipsin, omentin and vaspin are adipocytokines which are still not well examined.

Objective and hypotheses: To estimate the effect of 6 months GH therapy on serum concentrations of adipsin, omentin and vaspin in prepubertal children with isolated GHD.

Method: The 32 (22 boys, ten girls) non-obese, short children with GHD (mean height 117.9 cm, −2.77 SD, mean BMI −0.75 SD), mean age 8.87 years. Control group (CG) consisted of 18 (11 boys, nine girls) age matched healthy children (mean height 125.8 cm, −0.93 SD, mean BMI −0.28 SD). Serum fasting adipsin, omentin and vaspin were measured in all children: in CD group and in GHD children before and after 6 months of GH therapy. In statistical analysis t-student and U Mann–Whitney tests were applied.

Results: The mean serum concentrations of adipsin, omentin and vaspin did not differ significantly between children with GHD before start of GH treatment and control group. Mean adipsin concentration in GHD untreated patients and in CG children was 890.4 and 826.8 ng/ml respectively. Mean omentin concentration in GHD untreated patients and in CG children was 352.3 and 316.0 ng/ml respectively. Mean vaspin concentration in GHD untreated patients and in CG children was 0.126 and 0.123 ng/ml respectively. Adipsin and omentin concentrations were significantly lower after 6 months of therapy comparing to results before commencing GH therapy (890.4 vs 777.9 ng/ml, P<0.01 and 352.3 vs 314.5 ng/ml, P<0.05 respectively). Vaspin concentration was significantly higher after 6 months of therapy comparing to results before starting GH therapy (0.164 vs 0.106 ng/ml, P<0.05).

Conclusion: GH therapy causes lowering of adipsin and omentin and increasing of vaspin in non-obese children with GHD.

Funding: This work was supported the Department of Health Sciences University of Jan Kochanowski in Kielce (internal grant).

Volume 84

54th Annual ESPE (ESPE 2015)

Barcelona, Spain
01 Oct 2015 - 03 Oct 2015

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

Authors